The Impact of Gastric Juice pH on the Intraluminal Therapy for Helicobacter pylori Infection

Yu-Chio Wang, Yen-Po Chen, Cheng-Yu Ho, Ting-Wen Liu, Cheng-Hsin Chu, Horng-Yuan Wang, Tai-Cherng Liou, Yu-Chio Wang, Yen-Po Chen, Cheng-Yu Ho, Ting-Wen Liu, Cheng-Hsin Chu, Horng-Yuan Wang, Tai-Cherng Liou

Abstract

Background: Helicobacter pylori (H. pylori) can be topically eradicated in stomach lumen on endoscopic examination. The procedures of intraluminal therapy for H. pylori infection (ILTHPI) include the control of intragastric pH, mucolytic irrigation of the gastric mucosal surface, and a single-dose medicament containing antimicrobial agents.

Aims: To detect gastric juice pH and evaluate its impact on the success rate of ILTHPI.

Methods: We enrolled 324 patients with upper abdominal discomfort for endoscopic examinations. Among them, 13C-urea breath test was positive in 218 patients, where 100 underwent ILTHPI, and negative in 106. All patients had their gastric juice pH detected and set into three ranges, including normal acidity (pH < 4.0), low-level hypoacidity (pH 4.0-5.5), and high-level hypoacidity (pH ≥ 6.0). The impact of gastric juice pH on the success rate of ILTHPI was evaluated.

Results: Distribution of pH level showed no significant difference between two groups of H. pylori-infected patients (p = 0.942). The eradication rate of ILTHPI is significantly lower in patients with gastric juice pH below 4 (p < 0.001).

Conclusions: Detection of gastric juice pH in ILTHPI is extremely important. Rapid control of stomach pH at or above 4 for patients prior to ILTHPI is strongly recommended. (NCT03124420).

Keywords: Helicobacter pylori; acidity; endoscopy; gastric juice; therapy.

Conflict of interest statement

All authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study flow chart.

References

    1. Savoldi A., Carrara E., Graham D.Y., Conti M., Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: A Systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155:1372–1382.e17. doi: 10.1053/j.gastro.2018.07.007.
    1. WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. [(accessed on 16 May 2020)]; Available online: .
    1. Liou T.-C., Liao P.-H., Lin Y.-C., Chu C.-H., Shih S.-C. Intraluminal therapy for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2019;34:1337–1343. doi: 10.1111/jgh.14627.
    1. Marieb E.N., Hoehn K. Human Anatomy and Physiology. 8th ed. Vol. 32. Benjamin Cummings; San Francisco, CA, USA: 2010. p. 28.
    1. Xu X., Li W., Qin L., Yang W., Yu G., Wei Q. Relationship between Helicobacter pylori infection and obesity in Chinese adults: A systematic review with meta-analysis. PLoS ONE. 2019;14:e0221076. doi: 10.1371/journal.pone.0221076.
    1. Liao P.-H., Lin Y.-C., Chu C.-H., Shih S.-C., Liou T.-C. Colonization of Helicobacter pylori in the gastric cardia: A comparison between the UFT300 and CLO tests. JGH Open. 2018;2:93–96. doi: 10.1002/jgh3.12053.
    1. Wang Y., Liu S., Zhang Y., Bi C., Xiao Y., Lin R., Huang B., Tian D., Ying S., Su M. Helicobacter pylori infection and gastric cardia cancer in Chaoshan region. Microbes Infect. 2014;16:840–844. doi: 10.1016/j.micinf.2014.06.009.
    1. Sugimoto M., Furuta T., Shirai N., Kodaira C., Nishino M., Ikuma M., Ishizaki T., Hishida A. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007;12:317–323. doi: 10.1111/j.1523-5378.2007.00508.x.
    1. Erah P.O., Goddard A.F., Barrett D.A., Shaw P.N., Spiller R.C. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: Relevance to the treatment of Helicobacter pylori infection. J. Antimicrob. Chemother. 1997;39:5–12. doi: 10.1093/jac/39.1.5.
    1. Marcus E.A., Inatomi N., Nagami G.T., Sachs G., Scott D.R. The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin. Aliment. Pharmacol. Ther. 2012;36:972–979. doi: 10.1111/apt.12059.
    1. Cheng A., Sheng W.-H., Liou J.-M., Wang H.-P., Wu M.-S., Lin J.-T., Chang S.-C. Comparative in vitro antimicrobial susceptibility and synergistic activity of antimicrobial combinations against Helicobacter pylori isolates in Taiwan. J. Microbiol. Immunol. Infect. 2015;48:72–79. doi: 10.1016/j.jmii.2012.08.021.
    1. Suzuki S., Gotoda T., Kusano C., Iwatsuka K., Moriyama M. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-Day PPI-based low-dose clarithromycin triple therapy. Am. J. Gastroenterol. 2016;111:949–956. doi: 10.1038/ajg.2016.182.
    1. Hessey S.J., Spencer J., Wyatt J.I., Sobala G., Rathbone B.J., Axon A.T., Dixon M.F. Bacterial adhesion and disease activity in Helicobacter associated chronic gastritis. Gut. 1990;31:134–138. doi: 10.1136/gut.31.2.134.
    1. Atuma C., Strugala V., Allen A., Holm L. The adherent gastrointestinal mucus gel layer: Thickness and physical state in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 2001;280:G922–G929. doi: 10.1152/ajpgi.2001.280.5.G922.
    1. Johansson M.E., Sjövall H., Hansson G.C. The gastrointestinal mucus system in health and disease. Nat. Rev. Gastroenterol. Hepatol. 2013;10:352–361. doi: 10.1038/nrgastro.2013.35.
    1. Cao X., Bansil R., Bhaskar K.R., Turner B.S., Lamont J.T., Niu N., Afdhal N.H. pH-dependent conformational change of gastric mucin leads to sol-gel transition. Biophys. J. 1999;76:1250–1258. doi: 10.1016/S0006-3495(99)77288-7.
    1. Celli J.P., Turner B.S., Afdhal N.H., Ewoldt R.H., McKinley G.H., Bansil R., Erramilli S. Rheology of gastric mucin exhibits a pH-dependent sol−gel transition. Biomacromolecules. 2007;8:1580–1586. doi: 10.1021/bm0609691.
    1. Lai S.K., Wang Y.-Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009;61:158–171. doi: 10.1016/j.addr.2008.11.002.
    1. Samloff I.M. Peptic ulcer: The many proteinases of aggression. Gastroenterology. 1989;96:586–595. doi: 10.1016/S0016-5085(89)80054-X.
    1. Fan H.-Y., Wang J., Yan G.-C., Huo X.-H., Mu L.-J., Chu J.-K., Niu W.-W., Duan Z.-Y., Ma J.-C., Wang J., et al. Increasing gastric juice pH level prior to anti-Helicobacter pylori therapy may be beneficial to the healing of duodenal ulcers. Exp. Ther. Med. 2013;5:912–916. doi: 10.3892/etm.2013.880.
    1. Rektorschek M., Weeks D., Sachs G., Melchers K. Influence of pH on metabolism and urease activity of Helicobacter pylori. Gastroenterology. 1998;115:628–641. doi: 10.1016/S0016-5085(98)70142-8.
    1. Celli J.P., Turner B.S., Afdhal N., Keates S., Ghiran I., Kelly C.P., Ewoldt R.H., McKinley G.H., So P., Erramilli S., et al. Helicobacter pylori moves through mucus by reducing mucin viscoelasticity. Proc. Natl. Acad. Sci. USA. 2009;106:14321–14326. doi: 10.1073/pnas.0903438106.
    1. Cui Y., Zhou K., Strugatsky D., Wen Y., Sachs G., Zhou Z.H., Munson K. pH-dependent gating mechanism of the Helicobacter pylori urea channel revealed by cryo-EM. Sci. Adv. 2019;5:eaav8423. doi: 10.1126/sciadv.aav8423.
    1. Allen A., Flemström G. Gastroduodenal mucus bicarbonate barrier: Protection against acid and pepsin. Am. J. Physiol. Cell Physiol. 2005;288:C1–C19. doi: 10.1152/ajpcell.00102.2004.
    1. Croxen M.A., Sisson G., Melano R., Hoffman P.S. The Helicobacter pylori chemotaxis receptor TlpB (HP0103) is required for pH taxis and for colonization of the gastric mucosa. J. Bacteriol. 2006;188:2656–2665. doi: 10.1128/JB.188.7.2656-2665.2006.
    1. Valenzuela M., Cerda O., Toledo H. Overview on chemotaxis and acid resistance in Helicobacter pylori. Biol. Res. 2003;36:429–436. doi: 10.4067/S0716-97602003000300014.
    1. Ansari S., Yamaoka Y. Survival of Helicobacter pylori in gastric acidic territory. Helicobacter. 2017;22 doi: 10.1111/hel.12386.
    1. Merki H.S., Fimmel C.J., Walt R.P., Harre K., Röhmel J., Witzel L. Pattern of 24 hour intragastric acidity in active duodenal ulcer disease and in healthy controls. Gut. 1988;29:1583–1587. doi: 10.1136/gut.29.11.1583.
    1. Bell N.J.V., Hunt R.H. Time to maximum effect of lansoprazole on gastric pH in normal male volunteers. Aliment. Pharmacol. Ther. 1996;10:897–904. doi: 10.1046/j.1365-2036.1996.103242000.x.
    1. Sung J., Kim N., Lee J., Hwang Y.-J., Kim H.W., Chung J.W., Kim J.-W., Lee D.H. Associations among gastric juice pH, atrophic gastritis, intestinal metaplasia and Helicobacter pylori infection. Gut Liver. 2017;12:158–164. doi: 10.5009/gnl17063.
    1. Otake K., Sakurai Y., Nishida H., Fukui H., Tagawa Y., Yamasaki H., Karashima M., Otsuka K., Inatomi N. Characteristics of the novel potassium-competitive acid blocker Vonoprazan fumarate (TAK-438) Adv. Ther. 2016;33:1140–1157. doi: 10.1007/s12325-016-0345-2.
    1. Leal J., Smyth H.D.C., Ghosh D. Physicochemical properties of mucus and their impact on transmucosal drug delivery. Int. J. Pharm. 2017;532:555–572. doi: 10.1016/j.ijpharm.2017.09.018.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren